Phathom Pharmaceuticals (PHAT) PT Lowered to $58 at BMO Capital, Remains Bullish as Vonoprazan On Track
Tweet Send to a Friend
BMO Capital analyst Gary Nachman lowered the price target on Phathom Pharmaceuticals (NASDAQ: PHAT) to $58.00 (from $61.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
